Trinity Biotech plc
NASDAQ:TRIBMedical - Diagnostics & Research
-$0.51 today
- Market cap
- $117.96M
- Beta
- 1.00
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.27
Volume 0.00M
Average 1.34M
Returns on capital
Trinity Biotech plc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
51.9%
avg 174.1%
ROIC
-15.3%
avg -10.0%
ROA
-35.5%
avg -19.3%
Analysis
ROE is currently the strongest return metric at 51.9% versus its period average of 174.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
John Gillard | President, Chief Executive Officer, Company Secretary & Director | USD 1.14M | 45 | 29.17K | 2.88% |
Ronan O'Caoimh | Founder, Director & Executive Advisor | USD 60K | 70 | 2.92K | 0.29% |
James Walsh | Executive Director of Business Development & Executive Director | USD 48K | 68 | — | — |
Eibhlin Kelly | Chief Information Officer | — | 41 | — | — |
Jacqueline O'Neill | Director of Operations | — | 53 | — | — |
Paul Murphy | Interim Chief Financial Officer | — | — | 0 | <0.01% |
Jerry Lydon | Head of North America Commercial Operations | — | — | — | — |
Jordi Romero | Head of Commercial Operations - Europe | — | — | — | — |
Gary Keating | Chief Technology Officer | — | 53 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 1, 2027.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -11.2% | +35.9% (1yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -11.2% over three years. Forward estimates point to Revenue at +35.9% (1yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Trinity Biotech plc compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
No competitor data available.
Questions
Management questions
Common questions about TRIB's management, answered from reported figures.
Who manages TRIB?
Trinity Biotech plc (TRIB) lists 9 active executives. The top listed executive is Eibhlin Kelly, Chief Information Officer.
Are TRIB insiders buying or selling?
Recent insider activity shows net selling of $9.14M.
Continue the stock analysis
Jump to another research area for this company.